Mankind's revenue from operations rose to Rs 3,230 crore in Q3FY25, a 24 per cent Y-o-Y rise from Rs 2,607 crore reported in ...

Jefferies maintains a Buy rating on JB Pharma citing strong CDMO growth potential and a 34% upside. Know more about it.

Mankind Pharma's shares are in focus following a 16.5% YoY decline in Q3 net profit to Rs 385 crore, despite strong revenue ...

Mankind Pharma Ltd.'s share price declined more than 5% during early trade on Friday after the company's third-quarter ...

Ipca Laboratories Ltd.(down 1.45 per cent), Sun Pharmaceutical Industries Ltd.(down 0.88 per cent), Mankind Pharma Ltd.(down ...

Motilal Oswal is bullish on Mankind Pharma has recommended buy rating on the stock with a target price of Rs 3050 in its ...

Mankind Pharma's domestic business revenues grew by 16 per cent year-on-year, reaching Rs 2,773 crore in Q3FY25, compared to Rs 2,400 crore in Q3FY24. The company’s consumer healthcare segment saw a ...

Most pharma stocks traded in the red during Friday’s session, with the Nifty Pharma index falling 2.19% at 21,854.15. Dr.

Mankind Pharma's net profit fell 16.5% to Rs 384 crore in Q3 FY25, while revenue rose 24% to Rs 3,230 crore. The company's ...

The Board of Directors of Mankind Pharma Limited, at its meeting held today have approved the financial results of the ...

Mankind Pharma's Q3 net profit was impacted by the $1.6 billion acquisition of Bharat Serums and Vaccines (BSV), which came ...

India's Mankind Pharma reported a smaller-than-expected third-quarter profit on Thursday, hurt by a sharp rise in expenses.